Tuesday, March 19, 2024
Home News Pharma News

Pharma News

Health Europa brings you the latest Pharma News the field of European Healthcare & Social Care Policy.

anti-diabetic drugs

Anti-diabetic drugs may lower brain cancer risk, says the University of Bristol

Researchers from the University of Bristol have uncovered a potential link between long-term use of certain anti-diabetic drugs and a reduced risk of primary...
advanced Parkinson's disease

NHS offers groundbreaking portable drug infusion for advanced Parkinson’s disease patients

Hundreds of NHS patients grappling with advanced Parkinson's disease are poised to experience relief thanks to a groundbreaking portable drug infusion set to revolutionise...
monoclonal antibody

Tohoku University develops monoclonal antibody for HER2-positive breast cancer

Tohoku University have engineered a groundbreaking monoclonal antibody aimed at HER2-positive breast cancer.
cold chain

The critical vaccine cold chain

Dr Nenad Miljković from the European Association of Hospital Pharmacists (EAHP) outlines the critical role of cold chain storage in maintaining the efficacy and...
hormone replacement therapy

Over 500,00 women access affordable hormone replacement therapy through HRT PPC

Over 500,000 women in England have accessed more affordable hormone replacement therapy (HRT), the primary treatment for menopause symptoms.
drug delivery

BioNxt acquires cutting-edge equipment to boost drug delivery product manufacturing

BioNxt Solutions Inc. has proudly announced the acquisition of advanced coating and cutting equipment, marking a crucial stride in expanding its commercial manufacturing of...
lung tumours

Defence Therapeutics’ breakthrough in cancer treatment: AccuTOX® shows promise against lung tumours

Defence Therapeutics has announced the successful testing of a new formulation of its ACCUM-002TM Dimer CDCA-SV40 against lung tumours.
mRNA vaccine technology

Developing mRNA vaccine technology

Following the unprecedented development of vaccines during the COVID-19 pandemic, we spoke to Dinah Knotts about mRNA vaccine technology and what further opportunities it...
FDA approval

Defence Therapeutics granted FDA approval for Phase I Clinical Trial of AccuTOX®

Defence Therapeutics has announced a pivotal milestone: the U.S. Food and Drug Administration (FDA) has granted a green light with a "Study May Proceed"...
Sebelipase alfa

NHS approves life-saving Sebelipase alfa treatment for Wolman disease

The NHS has approved a life-saving treatment for babies and toddlers grappling with a rare and fatal genetic condition known as Wolman disease. This marks...
AccuTOX®

Defence Therapeutics applies to use AccuTOX® as an advanced tumour treatment

Defence Therapeutics has submitted an Investigational New Drug application for AccuTOX®, an injectable anticancer molecule.
vaccine technology

Defence Therapeutics awarded CIPO patent for vaccine technology

Defence Therapeutics has announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for the company's Canadian patent application no....
flu treatments

RECOVERY trial set to investigate revolutionary new flu treatments

The groundbreaking RECOVERY trial, celebrated for its discovery of four effective treatments for COVID-19, is broadening its horizons by venturing into the realm of...
AccuTOX®

AccuTOX® anticancer drug demonstrates exciting antigen cross-presentation

Defence Therapeutics Inc., a prominent Canadian biopharmaceutical company renowned for its work in immune-oncology vaccines and drug delivery technologies, has announced the discovery of...

Administration of AccuTOX™-chitosan inhibits the growth of established solid lymphoma in animals

Defence Therapeutics has announced that systemic administration of novel AccuTOX™-chitosan encapsulated formulation inhibits the growth of pre-established solid lymphoma resulting in their progressive shrinking...

Defence Therapeutics Inc. releases Accum® study revealing its anti-cancer properties

Defence Therapeutics Inc. have announced the publication of a peer-reviewed study on the anti-cancer properties of its unconjugated Accum®.
lipid nanoparticles

Accum®-mRNA lipid nanoparticles have double the antibody response of traditional mRNA vaccines

Defence Therapeutics has announced a groundbreaking achievement, demonstrating that its Accum®-mRNA lipid nanoparticles elicit twice the antibody response of mRNA-based vaccines. The company's encapsulation strategy,...
cancer drug resistance

Researchers discover new target to combat cancer drug resistance

In a groundbreaking development, scientists at the University of Queensland have pinpointed a novel drug target with immense promise in combating cancer drug resistance...

Cold chain challenges solved with collaboration

B Medical Systems has hosted a roundtable event at Medlab Asia – providing insights into the challenges of cold chain systems. During the Medlab Asia...
Accum® technology

How Defence’s Accum® technology is advancing cancer therapeutics

Industry-leading biotechnology pioneer Defence Therapeutics details how the company is advancing immune oncology through its revolutionary Accum® technology. Whether using an antibody, cell-based vaccine or...

Featured Special Reports

Health Special Reports

Health eBooks

Health Partners

Pin It on Pinterest